BioPharmSignal logoBioPharmSignal

Biotech News

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Cyclerion (CYCN)CyclerionClinical readout

– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept (“POC”) Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00

Open original release

Related news

BTAIBioXcel2026-04-08 11:00 EST

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

IKTInhibikase Therapeutics2026-04-07 12:00 EST

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

KTTAPasithea Therapeutics2026-06-30 11:00 EST

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

KTTAPasithea Therapeutics2026-06-16 11:00 EST

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

DNLIDenali Therapeutics2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

AXSMAxsome2026-06-26 11:00 EST

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

BTAIBioXcel2026-05-28 11:00 EST

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

ALKSAlkermes plc2026-04-01 11:00 EST

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

TSHATaysha Gene Therapies2026-06-22 12:00 EST

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

View all latest news

Cyclerion

Cyclerion was a biotechnology company focused on cyclic nucleotide biology and central nervous system or vascular-related disease programs before becoming a historical ticker. Its story reflected the challenge of turning a mechanistic platform into a durable drug franchise.

Recent company news

CYCNCyclerion2026-04-01 11:05 EST

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

CYCNCyclerion2026-02-17 12:00 EST

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

CYCNCyclerion2026-01-05 21:01 EST

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

CYCNCyclerion2025-09-23 20:01 EST

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

CYCNCyclerion2024-12-17 13:08 EST

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Stock data

Close
3.50 USD
Market cap
13.08M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States